

ASX ANNOUNCEMENT

Tuesday 21st July 2026

Upgrade to FY26 Guidance

IDT Australia Limited (ASX: IDT) (**IDT** or the **Company**) is pleased to announce an upgrade to its revenue and profit guidance for the financial year 2026 (FY26), reflecting favourable trading conditions and strong operational performance.

The Company is now expecting unaudited FY26 revenue from its three verticals to increase by 16.5% year-on-year (YoY) to \$16.8 million and for unaudited earnings before interest, tax, depreciation and amortisation (EBITDA) to improve significantly to -\$943K (vs. FY25: -\$6.3M).

	ACTUAL FY25	PREVIOUS FY26 GUIDANCE	NEW FY26 GUIDANCE ¹	% CHG (YOY)
REVENUE FROM 3 VERTICALS	\$14.4M	\$15M to \$16M	\$16.8M	+16.5%
DISBURSEMENTS	\$5.4M	~\$3M	\$3.6M	-33.7%
TOTAL REVENUE	\$19.8M	\$18M to \$19M	\$20.3M	+2.9%
EBITDA	-\$6.3M	-\$1.5M to -\$2M	-\$0.95M	+85.1%

The drivers behind the guidance upgrade include strong local and international demand momentum for IDT's world-class facilities and end-to-end drug manufacturing services, and cost savings running ahead of target. IDT will provide further details and outlook when it releases its full year results and audited accounts next month.

Industry Recognition

The traction from IDT's strategic transformation strategy has been acknowledged by IMAPAC, an Asia Pacific biopharma research and networking organisation, which presented IDT with two prestigious awards, **Overall RNA Manufacturing Excellence Award** and **Best Emerging RNA CDMO Award**, at the Asia-Pacific RNA Excellence Awards 2026 in Singapore on 30 June 2026.

These awards acknowledge the expertise, innovation, and dedication of IDT's team in advancing RNA research, development, and manufacturing. They also reinforce IDT's growing leadership position in the rapidly expanding RNA therapeutics sector.

Ends..../

¹ All figures subject to audit.

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.



Authorised by the Board of Directors of IDT Australia Limited.

For investor and media enquiries, please contact:

Brendon Lau

E: brendon@vantagepointpartners.com.au

M: +61 409 341 613

Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on IDT Australia's beliefs, assumptions, and expectations and on information currently available to IDT Australia.

All statements that address operating performance, events, or developments that IDT Australia or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of IDT Australia or the market it operates in.

IDT Australia believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. IDT Australia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of IDT Australia or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.